Earnings summaries and quarterly performance for Sensei Biotherapeutics.
Executive leadership at Sensei Biotherapeutics.
Board of directors at Sensei Biotherapeutics.
Research analysts covering Sensei Biotherapeutics.
Recent press releases and 8-K filings for SNSE.
SEED Therapeutics Initiates Phase 1 Trial for ST-01156
SNSE
Product Launch
New Projects/Investments
- SEED Therapeutics has dosed the first patient in its Phase 1a dose-escalation study of ST-01156, an oral RBM39 degrader for advanced solid tumors, with the primary objective to evaluate its safety and tolerability.
- ST-01156 has received U.S. FDA Orphan Drug Designation and Rare Pediatric Disease Designation for Ewing sarcoma.
- Eli Lilly and Co. and Eisai Co., Ltd. are cornerstone investors and research collaborators with SEED Therapeutics.
Jan 9, 2026, 4:20 PM
InnoCare Pharma Presents Positive Clinical Data for Mesutoclax at ASH Meeting
SNSE
New Projects/Investments
Product Launch
- InnoCare Pharma presented positive clinical data for its novel BCL2 inhibitor, Mesutoclax (ICP-248), at the 67th Annual Meeting of the American Society of Hematology (ASH).
- Mesutoclax monotherapy demonstrated remarkable efficacy in relapsed/refractory mantle cell lymphoma (MCL), achieving an 87.5% overall response rate and a 46.9% complete response rate in the 125 mg dose group, with a favorable safety profile.
- For chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), mesutoclax monotherapy or combined with orelabrutinib showed a 100% overall response rate in the 125 mg dose group for both treatment-naive and relapsed/refractory patients.
- The combination of mesutoclax and azacitidine (AZA) achieved a 92% composite complete response rate in treatment-naive acute myeloid leukemia (AML) patients, with a 0% 90-day mortality rate and a well-tolerated safety profile.
- InnoCare has two registrational clinical trials ongoing for Mesutoclax in CLL/SLL and MCL, and is expanding its AML study and launching a myelodysplastic syndrome (MDS) study globally.
Dec 9, 2025, 2:04 AM
Junshi Biosciences' NDA for Roconkibart Accepted by NMPA
SNSE
Product Launch
New Projects/Investments
- Shanghai Junshi Biosciences Co., Ltd announced that the National Medical Products Administration (NMPA) has accepted the New Drug Application (NDA) for its roconkibart injection (JS005).
- The NDA is for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
- The acceptance is based on a pivotal phase 3 clinical study involving 747 patients in China, which demonstrated roconkibart's superior efficacy to placebo and a favorable safety profile over 52 weeks.
- This milestone is considered a critical step in advancing Junshi Biosciences' autoimmune disease pipeline and transitioning the therapy from clinical research to real-world practice.
Dec 5, 2025, 3:19 PM
Sensei Biotherapeutics Reports Q3 2025 Financial Results and Initiates Strategic Review
SNSE
Earnings
Layoffs
M&A
- Sensei Biotherapeutics reported its Third Quarter 2025 financial results on November 14, 2025.
- The company announced the discontinuation of solnerstotug development and initiated a comprehensive review of strategic alternatives, which may include a sale of assets, licensing, or a sale of the company.
- To preserve cash, Sensei Biotherapeutics implemented a workforce reduction of approximately 65 percent.
- As of September 30, 2025, cash, cash equivalents and marketable securities were $25.0 million, and the net loss for Q3 2025 was $4.6 million.
Nov 14, 2025, 12:35 PM
Sensei Biotherapeutics Reports Q3 2025 Results, Discontinues Lead Product, and Initiates Strategic Review
SNSE
Earnings
Layoffs
M&A
- Sensei Biotherapeutics reported a net loss of $4.6 million for the third quarter of 2025, compared to a $7.3 million net loss for the same period in 2024.
- As of September 30, 2025, the company's cash, cash equivalents, and marketable securities totaled $25.0 million, a decrease from $41.3 million as of December 31, 2024.
- On October 30, 2025, the company announced its decision to discontinue the development of solnerstotug and initiated a comprehensive review of strategic alternatives to maximize shareholder value, which may include a sale of assets, licensing, collaborations, a sale of the company, a business combination, a merger, or an orderly wind-down of operations.
- In connection with this strategic review, Sensei Biotherapeutics implemented a workforce reduction of approximately 65 percent to preserve cash.
Nov 14, 2025, 12:30 PM
MaaT Pharma Presents Preclinical Data for MaaT034 at SITC Annual Meeting
SNSE
New Projects/Investments
- MaaT Pharma presented updated preclinical data for its next-generation drug candidate, MaaT034, at the 40th Society for Immunotherapy Cancer (SITC) Annual Meeting held from November 5 to 9, 2025.
- MaaT034 is a first-in-class co-cultured full ecosystem product from the MET-C platform, designed to optimize intestinal microbiome functions and improve patient responses to immunotherapy in combination with Immune Checkpoint Inhibitors.
- Preclinical data demonstrated compelling anti-tumor efficacy and immune activation in germ-free mouse models, with MaaT034 successfully engrafting in the gut and reproducing microbial functions.
- The combination of anti-PD1 and MaaT034 resulted in an 83.7% tumor growth reduction in tumor-bearing, germ-free mice, significantly outperforming the 10% reduction observed with anti-PD1 alone.
- These findings strongly support advancing MaaT034, a donor-independent synthetic microbiome therapy, into clinical development.
Nov 5, 2025, 6:30 AM
Sensei Biotherapeutics Initiates Strategic Review and Discontinues Solnerstotug Development
SNSE
M&A
Layoffs
Profit Warning
- Sensei Biotherapeutics, Inc. announced on October 30, 2025, that its Board of Directors has initiated a comprehensive review of strategic alternatives aimed at maximizing shareholder value.
- The company has decided to discontinue the development of solnerstotug after considering future funding needs and current capital market conditions.
- Strategic alternatives being explored include a sale of assets, licensing arrangements, collaborations, a sale of the Company, a business combination, a merger, or an orderly wind-down of operations.
- In connection with this strategic review, Sensei Biotherapeutics expects to implement a workforce reduction to preserve cash.
Oct 30, 2025, 1:05 PM
Sensei Biotherapeutics Provides Solnerstotug Clinical Update
SNSE
Product Launch
New Projects/Investments
- Sensei Biotherapeutics' Solnerstotug, a VISTA antibody, demonstrated an acceptable safety and tolerability profile in its Phase 1 dose escalation study, prioritizing the lack of severe Cytokine Release Syndrome (CRS) and an acceptable pharmacokinetic (PK) profile.
- The Solnerstotug/cemiplimab combination therapy showed clinical activity in a PD-(L)1 resistant population of solid tumors, with an encouraging overall 6-month Progression-Free Survival (PFS) rate of 37%.
- Data suggests the 15 mg/kg dose may have superior clinical activity, with all five responders observed at this dose and a PFS-6 of 50% at this level.
- The company plans Phase 2 studies including a randomized study in 2nd Line NSCLC and a single-arm study in Merkel Cell Carcinoma, with topline Phase 1 dose expansion data expected in October 2025.
Oct 20, 2025, 12:00 PM
Sensei Biotherapeutics Presents Positive Solnestretug Clinical Data and Phase 2 Plans
SNSE
New Projects/Investments
- Sensei Biotherapeutics presented the first progression-free survival data and the most advanced clinical data to date for its VISTA-targeting antibody, Solnestretug, highlighting its potential for patients with secondary resistance to checkpoint blockade.
- The Solnestretug regimen demonstrated a 6-month progression-free survival rate of 37% in patients previously treated with immunotherapy, with the 15 mg/kg dose cohort achieving almost 50%.
- The drug exhibited a favorable safety profile, with only one patient experiencing low-grade cytokine release syndrome and no grade 3 or 4 adverse events attributable to Solnestretug.
- Sensei plans to initiate Phase 2 studies in early 2026, with interim analyses in 2027 and top-line data expected in 2028, focusing on non-small cell lung cancer and Merkel cell carcinoma.
Oct 20, 2025, 12:00 PM
Sensei Biotherapeutics Presents Solnestretug Clinical Data and Phase II Plans
SNSE
New Projects/Investments
- Sensei Biotherapeutics' solnestretug regimen has presented the first progression-free survival data and the most advanced clinical data to date for any VISTA targeting antibody, demonstrating clinical activity, durability, and tolerability.
- In a cohort of 44 patients with hot tumors, the 6-month progression-free survival rate was 37%, with the 15 mg/kg dose showing almost 50% 6-month progression-free survival and all six observed responses. The safety profile was consistent with single-agent cemiplimab, with only one low-grade cytokine release syndrome event at the higher dose.
- The company plans to initiate Phase II studies in early 2026, with interim analyses expected in 2027 and top-line data available in 2028. The Phase II strategy includes a randomized study in non-small cell lung cancer and a single-arm study for accelerated approval in Merkel cell carcinoma.
Oct 20, 2025, 12:00 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more